GGrantIndex
← Search

CORE--TRANSGENIC MOUSE

$158,230P30FY2009CANIH

Fox Chase Cancer Center, Philadelphia PA

Investigators

Linked publications, trials & patents

Paper 39604567Paper 39602533Paper 39554190Paper 39546469Paper 39521739Paper 39514554Paper 39371220Paper 39345610Paper 39343653Paper 39223207Paper 39207123Paper 39189642Paper 39148468Paper 39137728Paper 39072643Paper 39060143Paper 39013784Paper 39003201Paper 38982062Paper 38976159Paper 38963567Paper 38914477Paper 38871720Paper 38865671Paper 38853421Paper 38835516Paper 38815457Paper 38811332Paper 38798370Paper 38766032Paper 38747616Paper 38678525Paper 38659828Paper 38639476Paper 38638131Paper 38600381Paper 38586274Paper 38586042Paper 38559274Paper 38547779Paper 38539515Paper 38464238Paper 38452871Paper 38432028Paper 38421650Paper 38377387Trial NCT04290585Trial NCT03177057Trial NCT02594826Trial NCT02132884Trial NCT02132858Trial NCT02132845Trial NCT02110953Trial NCT02092714Trial NCT02050009Trial NCT01982591Trial NCT01962948Trial NCT01934179Trial NCT01840150Trial NCT01462630Trial NCT01316757Trial NCT01212822Trial NCT00750009Trial NCT00509626Trial NCT00458588Trial NCT00436397Trial NCT00433524Trial NCT00084591Trial NCT00084539Trial NCT00084526Trial NCT00084513Trial NCT00066677Trial NCT00062322Trial NCT00062309Trial NCT00043108Trial NCT00039520Trial NCT00039507Trial NCT00022308Trial NCT00021398Trial NCT00021372Trial NCT00021346Trial NCT00021333Trial NCT00021320Trial NCT00005037Trial NCT00003264Trial NCT00003263Trial NCT00003109Patent 9533040Patent 9182383Patent 9101603Patent 8980258Patent 8685658Patent 8609437Patent 8580263Patent 8329873Patent 7332585Patent 7332580Patent 7129057Patent 6946275Patent 6617427

Abstract

The ability to introduce manipulated genes and delete or modify endogenous genes in the germline of animals is a major technological advance in biology, enabling investigators to answer questions about gene function which must be analyzed in a whole animal model system. Transgenic and knockout animals have been instrumental in providing insights into mechanisms of developmental gene regulation, cellular interactions within the immune system, and the effect of oncogenes on growth and differentiation. Demand for these services has grown significantly since the last review, approximately doubling every two years. A new Facility Manager was recruited in early 2000 with a specific expertise in generating knockout mice. In calendar year 1999, there were 21 requests for services. In 2003, 84 requests were completed (76 DNA Constructs Injected, 8 ES Cell Lines Injected). The number of peer-reviewed funded users has increased from nine at the last review to 15 in calendar year 2003. The use from these 15 peer-reviewed funded investigators represents six different Research Programs and all three Divisions of the Fox Chase Cancer Center (FCCC). Ninety-nine percent (99%) of Facility usage is by peer-reviewed funded investigators. As described in the last application, we planned to add needed cryopreservation services. Cryopreservation has been established and has become a routine service. It is currently used by 11 investigators. A total of 88 lines have been preserved to date. The availability of this service has resulted in several clear benefits, including the ability to bank mouse lines for future study, to relieve pressure on existing mouse colony space, to provide a means for propagating reproductively incompetent mouse lines, and to provide insurance against the loss of irreplaceable mouse lines should a catastrophic event occur in the mouse colony. The previous review noted a need to provide cryopreservation and gene knockout services as well as to increase Facility usage. All three points have been fully addressed. Both cryopreservation and gene targeting are now accomplished routinely, with a 100% success rate. Productivity and usage have increased by 200% and 100%, respectively, since 1998.

View original record on NIH RePORTER →